Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by DORIAN, C.
Right arrow Articles by KLAASSEN, C. D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by DORIAN, C.
Right arrow Articles by KLAASSEN, C. D.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1995 Oxford University Press

research-article

Protection by Zinc-Metallothionein (ZnMT) against Cadmium-Metallothionein-Induced Nephrotoxicity1

CATHERINE DORIAN2 and CURTIS D. KLAASSEN3

Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center Kansas City, Kansas 66160-7417

Received July 22, 1994; accepted December 5, 1994

In contrast to inorganic Cd, acute iv administration of Cd bound to metallothionein (CdMT) concentrates in renal tissue. This uptake of CdMT produces functional and morphological changes in kidneys, similar to those observed after chronic exposure to inorganic Cd. In order to examine the importance of the metal component of MT in the renal uptake of MT, the renal concentration of 35S after administration of [35S]ZnMT and [35S]CdMT was compared. Renal uptake of 35S from both CdMT and ZnMT was very rapid, with peak concentrations observed 15–30 min after administration. 35S in kidneys increased in a dose-dependent manner after administration of various doses of [35S]ZnMT, up to 1.3 µmole MT/kg; however, higher doses did not further increase renal 35S concentrations. A similar saturation of 35S reabsorption was observed for the renal uptake of [35S]CdMT. CdMT produced renal injury with doses as low as 0.26 µmol MT/kg (0.2 mg Cd/kg). In contrast, with a dose of ZnMT as high as 5.12 µmol MT/kg (2 mg Zn/kg), no histopathological changes were observed. Therefore, ZnMT appears to be nontoxic even though ZnMT delivers more MT to the kidney than does CdMT. Because ZnMT and CdMT are apparently handled by the same renal transport mechanism, the effects of ZnMT on 109CdMT renal uptake and nephrotoxicity were determined. One group of mice was given a nephrotoxic dose of 109CdMT (0.51 µmol MT/kg containing 0.4 mg Cd/kg, iv), and the other group received an equimolar dose of unlabeled ZnMT 1 min before 109CdMT administration. Renal function was evaluated by measuring urinary glucose and protein excretion, as well as histopathology. Marked renal toxicity was observed 24 hr after 109CdMT administration. In contrast, renal function appeared normal in mice receiving ZnMT before 109CdMT. However, a similar concentration of 109Cd was found in kidneys of both groups. The present results demonstrate that ZnMT is not only nontoxic to the kidney at a dose as high as 5 µmol MT/kg, but can also protect against the nephrotoxic effect of CdMT without decreasing renal Cd concentration.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.